PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.30
Bid: 8.20
Ask: 8.40
Change: -0.30 (-3.49%)
Spread: 0.20 (2.439%)
Open: 8.50
High: 8.50
Low: 8.30
Prev. Close: 8.60
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Agronomics Welcomes Marisa Drew as a Director

23 Feb 2023 07:00

RNS Number : 6296Q
Agronomics Limited
23 February 2023
 

23 February 2023

 

Agronomics Limited

 

("Agronomics" or the "Company")

 

Agronomics Welcomes Marisa Drew to the Board of Directors

Agronomics (ANIC:LSE), the leading listed company focused on the field of cellular agriculture is pleased to announce that it has today appointed Marisa Drew as an Independent Non-Executive Director. Marisa Drew is the inaugural Chief Sustainability Officer ("CSO") of Standard Chartered Bank Plc, responsible for setting the bank's sustainability strategy and the delivery of the firm's commitment to net zero carbon emissions by 2050 as well as overseeing the sustainable finance client-facing activities of the bank. Prior to this, she held the CSO role at Credit Suisse as well as being CEO of the Sustainability Strategy, Advisory & Finance Group. Marisa also Co-Chaired the Sustainability Leaders Committee, served on the ESG Steering Committee, the Climate Risk Strategy Steering Committee, and the UK Reputational Risk Committee of the bank. Marisa also sits on the member of the UK Financial Conduct Authority's Markets Practitioner Panel and has served on several High Level Working Groups ("HLG") sponsored by the World Economic Forum and the UN, including as co-chair of the HLG for Humanitarian Aid and the Oceans Panel.

As a globally recognised leader in sustainability, Marisa brings a vast wealth of experience to the Board and is thoroughly aligned with Agronomics' mission of bringing sustainable alternatives to agricultural products to consumers by investing in leading cellular agriculture companies.

Marisa Drew, Non-Executive Director of Agronomics commented: -

"I am delighted to be joining the Board of Agronomics at this truly exciting time in the field of cellular agriculture. Over the past year, Agronomics has grown its portfolio and is investing in ground-breaking companies and technologies creating a more sustainable protein production system. I look forward to working with my fellow board members to support the growth of the portfolio companies and scaling of the industry."

Jim Mellon, Co-Founder and Executive Director of Agronomics commented: -

"It is a pleasure to welcome Marisa to Agronomics' Board of Directors. Marisa brings with her a wealth of experience, particularly in the sphere of sustainability, and has a track record of achieving investor returns in her previous roles. As a recognised leader in sustainability, Marisa will be well equipped to work with Agronomics' senior team to enhance its portfolio and help advance the prospects for the field of cellular agriculture."

Marisa Danielle Drew (aged 58) is or has during the last five years been a director or partner of the following companies and partnerships:

Current:

Past:

Liberty Global PLC

Sunrise Communications Group AG

Cash & Rocket Holdings Ltd

Aspen Institute UK

 

 

Marisa Drew is also on the Advisory Boards of the Financial Conduct Authority (Expert Markets Practitioners Advisory Panel), The City of London Corporation and Room to Read, an education charity, and was on the Advisory Board at The Wharton School (EMEA Countries Advisory Board) until 2022.

 

Other than as disclosed above, there are no further disclosures to be made in accordance with AIM Rule 17 and paragraph (g) of Schedule Two of the AIM Rules for Companies.

About Agronomics

Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of over 20 companies in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

 

About Cellular Agriculture

Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter, or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.

 

Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5.

 

AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This combined with the Good Food Institute's estimate that a US $1.8 trillion investment will be required in order to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however still less than US$ 5 billion has been invested worldwide since the industry's inception in 2016.

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014, as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information please contact:

 

Agronomics

Limited

Beaumont

Cornish Limited

Canaccord

Genuity Limited

Cenkos

Securities Plc

Peterhouse Capital

Limited

 

TB Cardew

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Rees

Alex Aylen 

(Head of Equities)

Giles Balleny

Max Gould

Michael Johnson

Lucy Williams

Charles Goodfellow

 Ed Orlebar

Alistair Walker

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

 

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

+44 (0) 20 7930 0777

+44 (0) 7738 724 630

agronomics@tbcardew.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSEWFUFEDSEDE
Date   Source Headline
4th Dec 20197:00 amRNSUpdate on Placing and Final Results
11th Nov 20197:00 amRNSProposed Fundraise
29th Oct 20197:00 amRNSInvestment in Shiok Meats Pte. Ltd.
22nd Oct 20192:00 pmRNSCompany Newsletter
17th Oct 20197:00 amRNSInvestment in VitroLabs Inc
15th Oct 20197:00 amRNSInvestment in Rebellyous Foods
8th Oct 20197:00 amRNSNet Asset Value(s)
23rd Sep 20191:00 pmRNSAIM Rule 17 Notification
12th Sep 20197:00 amRNSInvestee Company Update
9th Sep 201911:55 amRNSHolding(s) in Company
5th Sep 20197:00 amRNSSeed Investment in Bond Pets LLC
29th Aug 20197:00 amRNSAgronomics Participates in BlueNalu Fund Raise
28th Aug 20199:42 amRNSNew website launched
27th Aug 20191:21 pmRNSInvestee company Update: Blue Nalu, Inc
12th Aug 201912:51 pmRNSHolding(s) in Company
5th Aug 20197:00 amRNSHolding(s) in Company
31st Jul 20197:00 amRNSNet Asset Value(s)
29th Jul 20197:00 amRNSInvestment in Simply Foods, Inc. (New Age Meats)
5th Jul 20194:40 pmRNSSecond Price Monitoring Extn
5th Jul 20194:35 pmRNSPrice Monitoring Extension
3rd Jul 201912:58 pmRNSResult of Meeting
17th Jun 20192:05 pmRNSSecond Price Monitoring Extn
17th Jun 20192:00 pmRNSPrice Monitoring Extension
17th Jun 201911:00 amRNSPrice Monitoring Extension
13th Jun 20197:00 amRNSEquity Fundraise Closes at £4.5 million
10th Jun 20197:00 amRNSProposed Equity Fundraise
31st May 20199:30 amRNSBoard Appointments
16th Apr 20191:01 pmRNSResult of Meeting
10th Apr 20197:00 amRNSNet Asset Value
29th Mar 20197:00 amRNSCircular and Notice of General Meeting
29th Mar 20197:00 amRNSHalf-year Report
7th Feb 20197:00 amRNSNet Asset Value(s)
28th Dec 20182:20 pmRNSFinal Results
24th Oct 20187:00 amRNSNet Asset Value(s)
16th Aug 20187:00 amRNSInvestment in Blue Nalu, Inc.
18th Jul 20187:00 amRNSNet Asset Value(s)
28th Jun 20187:00 amRNSInvestee Company Update: Summit Therapeutics plc
23rd Apr 20187:00 amRNSNet Asset Value(s)
27th Mar 20189:30 amRNSHalf-year Report
9th Feb 201812:31 pmRNSResult of AGM
8th Feb 20187:00 amRNSChange of Adviser
22nd Jan 20187:00 amRNSNet Asset Value(s)
28th Dec 20174:49 pmRNSFinal Results
19th Oct 20177:00 amRNSNet Asset Value(s)
20th Jul 201711:00 amRNSNAV & Investment in AgeX Therapeutics Inc.
25th Apr 20177:00 amRNSRedemption of Interest in Magna Biopharma Fund
12th Apr 20177:00 amRNSNet Asset Value(s)
29th Mar 20177:00 amRNSHalf-year Report
10th Feb 20175:29 pmRNSResult of AGM
12th Jan 20177:00 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.